Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 8/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 8/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 8/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.36 |
| ▸ | PRKDC | P78527 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24640 | 1.00 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Benzene SCHEMBL28791218 | 0.96 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Purine SCHEMBL28553167 | 0.80 | PI4KA (0.49) | PI4KAPI4K2BPI4K2API4KBXDH | |
| SCHEMBL7216713 | 0.78 | TDP1 (0.50) | PI4KAPI4K2BPI4K2API4KBXDH | |
| SCHEMBL8652766 | 0.78 | LMNA (0.54) | PI4KAPI4K2BPI4K2API4KBXDH | |
| SCHEMBL3445228 | 0.74 | DYRK1A (0.39) | — | |
| SCHEMBL7644350 | 0.74 | — | — | |
| SCHEMBL14322494 | 0.74 | PDPK1 (0.38) | XDHLMNA | |
| SCHEMBL5134210 | 0.68 | — | — | |
| SCHEMBL30492908 | 0.68 | PTPN11 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043082-A2 | COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS | THE BROAD INSTITUTE, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2025038970-A1 | MODIFIED OLIGONUCLEOTIDES CONTAINING MULTIPLE OLIGONUCLEOTIDES | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038971-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4499835-A2 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | Praxis Precision Medicines, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| EP-4466074-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | The Broad Institute Inc. (US) | 2024-11-27 | — | — | EP | claimed |
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| CN-117795071-A | Antisense oligonucleotides for preventing renal dysfunction caused by endothelial dysfunction through inhibition of ephrin-B2 | 马克斯·普朗克科学促进学会 | 2024-03-29 | — | — | CN | claimed |
| WO-2023141474-A9 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2023192885-A2 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023141474-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| CN-114761026-A | Compositions and methods for in vivo synthesis of non-native polypeptides | 斯克利普斯研究所 | 2022-07-15 | — | — | CN | claimed |
| EP-4743577-A1 | RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF | Korro Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4739778-A2 | RNA MOLECULE | Imperial College Innovations Limited (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-20260109976-A1 | SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS | RNAV8 BIO INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720338-A1 | METHODS OF MAKING BARRIERS INCLUDING NANOPORES AND CROSS-LINKED AMPHIPHILIC MOLECULES, AND BARRIERS FORMED USING SAME | Illumina, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3976788-A1 | OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE | Deep Genomics Incorporated (CA) | 2022-04-06 | — | — | EP | disclosed |
| EP-3387132-B1 | APTAMERS, NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES, SYNTHETIC ANTIBODIES COMPOSITIONS FOR DETECTING PRRS VIRUSES AND TREATING PRRS VIRUS INFECTION | AEROVIRUS TECH INC (CA) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022066647-A1 | USE OF CRISPR-CAS ENDONUCLEASES FOR PLANT GENOME ENGINEERING | INARI AGRICULTURE TECHNOLOGY, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022055726-A1 | DETECTING NUCLEIC ACIDS USING SUGAR-LECTIN COUPLINGS | ILLUMINA, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109976-A1 | SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS | UPF1, RNGTT, NSUN3 | PI4KA 1430/4885PI4K2B 853/4885PI4K2A 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.